Patisiran Sodium
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Patisiran Sodium |
| DrugBank ID | DB14582 |
| Brand Names (EU) | Onpattro |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 90.65% |
Approved Indication (EMA)
Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | dermatitis | 90.65% | DL |
| 2 | hydroa vacciniforme, familial | 90.08% | DL |
| 3 | amyopathic dermatomyositis | 90.07% | DL |
| 4 | acne keloid | 90.04% | DL |
| 5 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 90.01% | DL |
| 6 | neonatal dermatomyositis | 89.92% | DL |
| 7 | acrodermatitis chronica atrophicans | 89.14% | DL |
| 8 | Smouldering systemic mastocytosis | 85.13% | DL |
| 9 | overactive bladder (disease) | 84.90% | DL |
| 10 | lymphoadenopathic mastocytosis with eosinophilia | 84.62% | DL |
| 11 | systemic mastocytosis | 84.61% | DL |
| 12 | angioedema | 84.01% | DL |
| 13 | gastrin secretion abnormality | 83.02% | DL |
| 14 | low compliance bladder | 81.08% | DL |
| 15 | hepatic infarction | 79.63% | DL |
| 16 | HER2 positive breast carcinoma | 79.19% | DL |
| 17 | peliosis hepatis | 79.18% | DL |
| 18 | hepatic veno-occlusive disease | 79.01% | DL |
| 19 | bladder neck obstruction | 78.55% | DL |
| 20 | mixed-type autoimmune hemolytic anemia | 78.44% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.